Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Medinotec (MDNC) EBITDA Margin (2022 - 2025)

Medinotec filings provide 4 years of EBITDA Margin readings, the most recent being 26.13% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1458.0% to 26.13% in Q4 2025 year-over-year; TTM through Nov 2025 was 22.44%, a 1290.0% increase, with the full-year FY2025 number at 23.08%, up 3083.0% from a year prior.
  • EBITDA Margin hit 26.13% in Q4 2025 for Medinotec, up from 11.11% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 40.99% in Q1 2025 to a low of 108.23% in Q3 2022.
  • Median EBITDA Margin over the past 4 years was 4.34% (2025), compared with a mean of 5.18%.
  • The widest YoY moves for EBITDA Margin: up 9232bps in 2023, down -1198bps in 2023.
  • Medinotec's EBITDA Margin stood at 12.58% in 2022, then tumbled by -95bps to 24.56% in 2023, then soared by 147bps to 11.54% in 2024, then surged by 126bps to 26.13% in 2025.
  • The last three reported values for EBITDA Margin were 26.13% (Q4 2025), 11.11% (Q3 2025), and 4.59% (Q2 2025) per Business Quant data.